GE Healthcare has received marketing clearance from Health Canada for its DaTscan imaging agent.
DaTscan (ioflupane iodine-123 injection) is used with SPECT to image the striatum of the brain in patients with suspected parkinsonian syndrome, which includes Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
While DaTscan is not designed to differentiate between the three aforementioned conditions, clinicians can use the radiopharmaceutical with SPECT to help distinguish between parkinsonian syndrome and essential tremor.
GE said it plans to make DaTscan commercially available in Canada early this year.
